	US 7,514,066 B2
	Targeted combination immunotherapy of cancer and infectious diseases
Gary L. Griffiths, Morristown, N.J. (US); Hans J. Hansen, Picayune, Miss. (US); and David M. Goldenberg, Mendham, N.J. (US)
Assigned to Immunomedics, Inc., Morris Plains, N.J. (US)
Filed on Oct. 15, 2007, as Appl. No. 11/872,139.
Application 11/872139 is a division of application No. 10/361026, filed on Feb. 10, 2003, granted, now 7,300,644.
Application 10/361026 is a continuation of application No. 09/597580, filed on Jun. 20, 2000, granted, now 7,011,812.
Application 09/597580 is a continuation in part of application No. 09/184950, granted, now 6,077,499, previously published as PCT/US97/07395, filed on May 02, 1997.
Claims priority of provisional application 60/017011, filed on May 03, 1996.
Prior Publication US 2008/0031813 A1, Feb. 07, 2008
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 51/00 (2006.01); A61M 36/14 (2006.01)

U.S. Cl. 424—1.49 [424/1.11; 424/1.65; 424/178.1; 424/130.1]

20 Claims

1. A method of tumor therapy in a patient, comprising:

(A) administering a therapeutic naked antibody or a first conjugate comprising a multispecific antibody or antigen-binding fragment thereof and a first therapeutic agent, wherein the multispecific antibody selectively binds to (i) a marker substance produced by the tumor and (ii) to a hapten or to a second therapeutic agent;

(B) optionally, administering a clearing agent; and

(C) administering a second therapeutic agent or a second conjugate comprising a hapten to which said first conjugate binds and a second therapeutic agent, wherein the second therapeutic agent is the same as or different from the first therapeutic agent and wherein the first and second therapeutic agents are selected from the group consisting of radionuclides, cytokines, drugs, toxins, antibodies and oligonucleotides.